Navigation Links
XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Date:8/19/2007

tion. For the six months ended June 30, 2007 and 2006, the Company's loss of $14.6 million and $7.3 million, respectively, included $1.0 million and $1.2 million, respectively, of non-cash stock option compensation expense.

Ron Bentsur, Chief Executive Officer of XTL, commented, "From a financial standpoint our spend over the first 6 months, excluding the extraordinary payment associated with the in-licensing of Bicifadine, was slightly below plan. We have been planning our Phase IIb study for Bicifadine in diabetic neuropathic pain and are looking forward to starting that study shortly. As a member of the SNRI class, a proven class in neuropathic pain, and as a drug candidate that has demonstrated anti-pain activity in multiple clinical trials, we believe that Bicifadine represents a very compelling later-stage opportunity." Mr. Bentsur added, "We are very excited about the pending commencement of the Phase IIb clinical study for Bicifadine as we strive to increase investor awareness to this undervalued opportunity."

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development and commercialization of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Cautionary Statement

Some of the statement
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 2Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 3Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 4Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 5China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income 2China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income 3Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval) 2Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval) 3Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval) 4Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval) 5
Breaking Biology News(10 mins): Killer catfish? Venomous species surprisingly common, study finds 2Climate projections underestimate CO2 impact 2University of Texas Southwestern Medical Center researcher wins Avanti Award in lipids 2New National Poll Finds Americans Strongly Opposed to Cutting Medicare Payments for Nursing Home Care as a Means of Financing Health Care Reform 55742 1New National Poll Finds Americans Strongly Opposed to Cutting Medicare Payments for Nursing Home Care as a Means of Financing Health Care Reform 55742 2New National Poll Finds Americans Strongly Opposed to Cutting Medicare Payments for Nursing Home Care as a Means of Financing Health Care Reform 55742 3New National Poll Finds Americans Strongly Opposed to Cutting Medicare Payments for Nursing Home Care as a Means of Financing Health Care Reform 55742 4Noteworthy Medical Systems Demonstrates National Health Information Network 28NHIN 29 Interoperability 55739 1Noteworthy Medical Systems Demonstrates National Health Information Network 28NHIN 29 Interoperability 55739 2Noteworthy Medical Systems Demonstrates National Health Information Network 28NHIN 29 Interoperability 55739 3Do Good When You Shop and Help Educate a Generation of Healthy Kids 55736 1Do Good When You Shop and Help Educate a Generation of Healthy Kids 55736 2